Evaluation of Pneumococcal Vaccine Formulations in Young Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

January 15, 2009

Study Completion Date

January 15, 2009

Conditions
Infections, Streptococcal
Interventions
BIOLOGICAL

Pneumococcal vaccine GSK2189242A

Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested

BIOLOGICAL

Pneumo 23™

One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2

Trial Locations (1)

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00707798 - Evaluation of Pneumococcal Vaccine Formulations in Young Adults | Biotech Hunter | Biotech Hunter